Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

PRESS RELEASE FDA Approval

21/10/2021

Sumitomo Dainippon Pharma Co., Ltd.

CAMBRIDGE, Mass. & BASEL, Switzerland, October 8, 2021 (GLOBE NEWSWIRE) – Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus tissue‐agdc), a one‐time regenerative tissue‐based therapy for immune reconstitution in pediatric patients with congenital athymia.

Related News

Medicom Canadian mask facility begins producing new pediatric procedure and tie-on surgical masks

To discover more on this topic, please tap 'Read more'.

15/02/2021

PRESS RELEASE Product Launch

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us